Jonathan K. L. Mak, Kathryn Choon Beng Tan, Juulia Jylhävä, Sara Hägg, Ching-Lung Cheung
{"title":"两项前瞻性队列研究:步行速度与癌症风险","authors":"Jonathan K. L. Mak, Kathryn Choon Beng Tan, Juulia Jylhävä, Sara Hägg, Ching-Lung Cheung","doi":"10.1002/jcsm.13792","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Walking speed is a reliable marker of sarcopenia and a strong predictor of mortality, but its relationship with cancer incidence remains largely unexplored. We aimed to investigate the association between walking speed and the risk of any cancer and five common cancers, including lung, breast, colorectum, prostate, and stomach, and to explore potential mediation by biomarkers of inflammation, and lipid and glucose metabolism.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The primary analysis was conducted in 431 598 participants from the UK Biobank (mean age 56.3 [SD 8.1] years at baseline), and the generalizability of findings was further tested in 1311 participants from the Hong Kong Osteoporosis Study (HKOS; mean age 57.8 [SD 11.9] years). Walking speed was self-reported in the UK Biobank and measured using a timed 6-m walk test in the HKOS. Incident cancer cases were identified from electronic health records. We used Cox models, adjusted for age, sex, height, body mass index, socioeconomic, lifestyle factors, family history of cancer, and grip strength, to estimate the association between walking speed and cancer incidence. Single and multiple mediator models were performed in the UK Biobank to examine the mediating effects of C-reactive protein (CRP), white blood cell (WBC) count, total cholesterol, low-density lipoprotein (LDL) cholesterol, and glucose levels.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Over a median follow-up of 10.9 and 6.9 years, 11.7% and 5.0% of the UK Biobank and HKOS participants were diagnosed with cancer, respectively. In the UK Biobank, those reported a brisk vs. slow walking pace had a 13% lower risk of any cancer (95% CI 0.84–0.90). Similarly, HKOS participants with a faster walking speed (≥ 1.0 vs. < 1.0 m/s) had a 45% reduced risk of any cancer (95% CI 0.31–0.98). In the UK Biobank, brisk walking pace was associated with a significantly decreased risk of lung cancer (hazard ratio [HR] 0.47, 95% CI 0.42–0.53) and a slightly increased risk of prostate cancer (HR 1.11, 95% CI 1.02–1.21). CRP, WBC count, total cholesterol, and LDL cholesterol significantly mediated the association between brisk walking pace and any cancer, with proportions of mediation being 6.4% (95% CI 4.4–8.7%), 11.4% (8.4–17.1%), 9.3% (7.1–12.9%), and 8.3% (6.1–11.9%), respectively. The combined mediated proportion of all five potential mediators was 25.9% (19.5–37.2%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Faster walking speed, whether self-reported or measured, is associated with a reduced risk of cancer development. This association appears to be partially mediated by lower inflammation and improved lipid profiles.</p>\n </section>\n </div>","PeriodicalId":48911,"journal":{"name":"Journal of Cachexia Sarcopenia and Muscle","volume":"16 3","pages":""},"PeriodicalIF":9.4000,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13792","citationCount":"0","resultStr":"{\"title\":\"Walking Speed and Risk of Cancer in Two Prospective Cohort Studies\",\"authors\":\"Jonathan K. L. Mak, Kathryn Choon Beng Tan, Juulia Jylhävä, Sara Hägg, Ching-Lung Cheung\",\"doi\":\"10.1002/jcsm.13792\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Walking speed is a reliable marker of sarcopenia and a strong predictor of mortality, but its relationship with cancer incidence remains largely unexplored. We aimed to investigate the association between walking speed and the risk of any cancer and five common cancers, including lung, breast, colorectum, prostate, and stomach, and to explore potential mediation by biomarkers of inflammation, and lipid and glucose metabolism.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The primary analysis was conducted in 431 598 participants from the UK Biobank (mean age 56.3 [SD 8.1] years at baseline), and the generalizability of findings was further tested in 1311 participants from the Hong Kong Osteoporosis Study (HKOS; mean age 57.8 [SD 11.9] years). Walking speed was self-reported in the UK Biobank and measured using a timed 6-m walk test in the HKOS. Incident cancer cases were identified from electronic health records. We used Cox models, adjusted for age, sex, height, body mass index, socioeconomic, lifestyle factors, family history of cancer, and grip strength, to estimate the association between walking speed and cancer incidence. Single and multiple mediator models were performed in the UK Biobank to examine the mediating effects of C-reactive protein (CRP), white blood cell (WBC) count, total cholesterol, low-density lipoprotein (LDL) cholesterol, and glucose levels.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Over a median follow-up of 10.9 and 6.9 years, 11.7% and 5.0% of the UK Biobank and HKOS participants were diagnosed with cancer, respectively. In the UK Biobank, those reported a brisk vs. slow walking pace had a 13% lower risk of any cancer (95% CI 0.84–0.90). Similarly, HKOS participants with a faster walking speed (≥ 1.0 vs. < 1.0 m/s) had a 45% reduced risk of any cancer (95% CI 0.31–0.98). In the UK Biobank, brisk walking pace was associated with a significantly decreased risk of lung cancer (hazard ratio [HR] 0.47, 95% CI 0.42–0.53) and a slightly increased risk of prostate cancer (HR 1.11, 95% CI 1.02–1.21). CRP, WBC count, total cholesterol, and LDL cholesterol significantly mediated the association between brisk walking pace and any cancer, with proportions of mediation being 6.4% (95% CI 4.4–8.7%), 11.4% (8.4–17.1%), 9.3% (7.1–12.9%), and 8.3% (6.1–11.9%), respectively. The combined mediated proportion of all five potential mediators was 25.9% (19.5–37.2%).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Faster walking speed, whether self-reported or measured, is associated with a reduced risk of cancer development. This association appears to be partially mediated by lower inflammation and improved lipid profiles.</p>\\n </section>\\n </div>\",\"PeriodicalId\":48911,\"journal\":{\"name\":\"Journal of Cachexia Sarcopenia and Muscle\",\"volume\":\"16 3\",\"pages\":\"\"},\"PeriodicalIF\":9.4000,\"publicationDate\":\"2025-04-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13792\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cachexia Sarcopenia and Muscle\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jcsm.13792\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cachexia Sarcopenia and Muscle","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcsm.13792","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
步行速度是肌肉减少症的可靠标志,也是死亡率的有力预测指标,但其与癌症发病率的关系仍未得到充分研究。我们的目的是研究步行速度与任何癌症和五种常见癌症(包括肺癌、乳腺癌、结直肠癌、前列腺癌和胃癌)风险之间的关系,并探索炎症、脂质和葡萄糖代谢等生物标志物的潜在介导作用。方法对来自英国生物银行(UK Biobank)的43598名参与者(基线时平均年龄56.3岁[SD 8.1]岁)进行了初步分析,并对来自香港骨质疏松症研究(HKOS;平均年龄57.8 [SD 11.9]岁)。步行速度在英国生物银行自行报告,并在香港天文台使用定时6米步行测试来测量。从电子健康记录中确定偶发癌症病例。我们使用Cox模型,调整了年龄、性别、身高、体重指数、社会经济、生活方式因素、癌症家族史和握力,以估计步行速度与癌症发病率之间的关系。在UK Biobank中建立了单介质和多介质模型,以检查c反应蛋白(CRP)、白细胞(WBC)计数、总胆固醇、低密度脂蛋白(LDL)胆固醇和葡萄糖水平的中介作用。结果在中位随访10.9年和6.9年期间,英国生物银行和香港癌症研究所的参与者分别有11.7%和5.0%被诊断为癌症。在英国生物银行(UK Biobank),快步走和慢步走的人患任何癌症的风险降低了13%(95%可信区间0.84-0.90)。同样,步行速度较快的HKOS参与者(≥1.0 m/s vs. 1.0 m/s)患任何癌症的风险降低45% (95% CI 0.31-0.98)。在UK Biobank中,快走速度与肺癌风险的显著降低(风险比[HR] 0.47, 95% CI 0.42-0.53)和前列腺癌风险的略微增加(风险比[HR] 1.11, 95% CI 1.02-1.21)相关。CRP、WBC计数、总胆固醇和LDL胆固醇显著介导了快走速度与任何癌症之间的关联,其中介比例分别为6.4% (95% CI 4.4-8.7%)、11.4%(8.4-17.1%)、9.3%(7.1-12.9%)和8.3%(6.1-11.9%)。5种潜在介质的联合介导比例为25.9%(19.5-37.2%)。结论:更快的步行速度,无论是自我报告还是测量,都与降低癌症发展风险有关。这种关联似乎部分由较低的炎症和改善的脂质谱介导。
Walking Speed and Risk of Cancer in Two Prospective Cohort Studies
Background
Walking speed is a reliable marker of sarcopenia and a strong predictor of mortality, but its relationship with cancer incidence remains largely unexplored. We aimed to investigate the association between walking speed and the risk of any cancer and five common cancers, including lung, breast, colorectum, prostate, and stomach, and to explore potential mediation by biomarkers of inflammation, and lipid and glucose metabolism.
Methods
The primary analysis was conducted in 431 598 participants from the UK Biobank (mean age 56.3 [SD 8.1] years at baseline), and the generalizability of findings was further tested in 1311 participants from the Hong Kong Osteoporosis Study (HKOS; mean age 57.8 [SD 11.9] years). Walking speed was self-reported in the UK Biobank and measured using a timed 6-m walk test in the HKOS. Incident cancer cases were identified from electronic health records. We used Cox models, adjusted for age, sex, height, body mass index, socioeconomic, lifestyle factors, family history of cancer, and grip strength, to estimate the association between walking speed and cancer incidence. Single and multiple mediator models were performed in the UK Biobank to examine the mediating effects of C-reactive protein (CRP), white blood cell (WBC) count, total cholesterol, low-density lipoprotein (LDL) cholesterol, and glucose levels.
Results
Over a median follow-up of 10.9 and 6.9 years, 11.7% and 5.0% of the UK Biobank and HKOS participants were diagnosed with cancer, respectively. In the UK Biobank, those reported a brisk vs. slow walking pace had a 13% lower risk of any cancer (95% CI 0.84–0.90). Similarly, HKOS participants with a faster walking speed (≥ 1.0 vs. < 1.0 m/s) had a 45% reduced risk of any cancer (95% CI 0.31–0.98). In the UK Biobank, brisk walking pace was associated with a significantly decreased risk of lung cancer (hazard ratio [HR] 0.47, 95% CI 0.42–0.53) and a slightly increased risk of prostate cancer (HR 1.11, 95% CI 1.02–1.21). CRP, WBC count, total cholesterol, and LDL cholesterol significantly mediated the association between brisk walking pace and any cancer, with proportions of mediation being 6.4% (95% CI 4.4–8.7%), 11.4% (8.4–17.1%), 9.3% (7.1–12.9%), and 8.3% (6.1–11.9%), respectively. The combined mediated proportion of all five potential mediators was 25.9% (19.5–37.2%).
Conclusion
Faster walking speed, whether self-reported or measured, is associated with a reduced risk of cancer development. This association appears to be partially mediated by lower inflammation and improved lipid profiles.
期刊介绍:
The Journal of Cachexia, Sarcopenia and Muscle is a peer-reviewed international journal dedicated to publishing materials related to cachexia and sarcopenia, as well as body composition and its physiological and pathophysiological changes across the lifespan and in response to various illnesses from all fields of life sciences. The journal aims to provide a reliable resource for professionals interested in related research or involved in the clinical care of affected patients, such as those suffering from AIDS, cancer, chronic heart failure, chronic lung disease, liver cirrhosis, chronic kidney failure, rheumatoid arthritis, or sepsis.